FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR TMB Consortium Develops a TMB Calibration Tool October 13, 2021 EMA Recommends Granting a Marketing Authorisation for Tislelizumab August 4, 2023 Representation, retention and hope – how a mentorship scheme is helping... October 25, 2022 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... September 23, 2024 Load more HOT NEWS Autumn and Letting Go Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... Patient Guide in Testicular Cancer Now Available Also in Italian
